stockrow
Saturday 7 November 2026
Export RARE’s income statement to Excel — free account
Ultragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024.
- Revenue
- +8.13%
- EPS
- +36.2%
- Free cash flow
- +12.5%
Quarter to September 2026, against a year earlier
15.43
0.14
−0.90%
Follow RARE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.10 | 4.75 | 3.15 | 3.37 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(35.69) | (35.08) | (10.70) | (22.68) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.74 | 4.34 | 2.53 | 2.36 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.90) | (6.41) | (3.41) | (3.41) | |
EV/FCF |
(2.84) | (6.30) | (3.34) | (3.26) | |
Quick Ratio |
1.11 | 1.40 | 1.64 | 2.18 | |
Current Ratio |
1.40 | 1.73 | 2.02 | 2.48 | |
Net Debt/EBITDA |
2.63 | 4.36 | 2.55 | 6.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.61 | 0.56 | 0.51 | 0.44 | |
Operating CF/Net income |
0.36 | 1.05 | 1.06 | 0.78 | |
Capex/Depreciation |
(0.22) | (0.12) | (0.86) | (0.11) | |
Interest Coverage |
(5.50) | (3.41) | (8.05) | (5.65) | |
Research and Development Expense of Revenue |
89.02% | 78.04% | 137.50% | 98.07% | |
Selling, General and Administrative Expense of Revenue |
56.07% | 41.12% | 64.71% | 42.51% | |
Intangible Assets out of Total Assets |
0.18 | 0.17 | 0.17 | 0.14 | |
Share Based Compensation of Revenue |
19.65% | 15.89% | 22.06% | 17.87% | |
Graham Net Nets |
(0.66) | (0.28) | (0.42) | (0.29) | |
Graham Number |
20.73 | 19.37 | 17.96 | 10.33 | |
Earnings Yield |
(34.50%) | (17.49%) | (29.16%) | (25.39%) | |
Free Cash Flow Yield |
(29.13%) | (14.52%) | (24.10%) | (21.47%) | |
Revenue per Share |
1.69 | 2.10 | 1.35 | 2.10 | |
Operating CF per Share |
(0.42) | (0.95) | (1.96) | (1.01) | |
Capex per Share |
(0.02) | (0.01) | (0.06) | (0.01) | |
Free Cash Flow per Share |
(0.44) | (0.96) | (2.02) | (1.02) | |
Cash per Share |
2.61 | 2.87 | 4.11 | 6.90 | |
Shareholders Equity per Share |
(3.68) | (2.86) | (2.35) | (0.81) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.68) | (2.86) | (2.35) | (0.81) | |
Free Cash Flow |
(45.00) | (98.00) | (203.00) | (101.00) | |
Working Capital |
155.00 | 255.00 | 332.00 | 567.00 | |
Capital Expenditures |
(2.00) | (1.00) | (6.00) | (1.00) | |
Net Current Asset Value |
(1,019.00) | (949.00) | (875.00) | (661.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.04 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
139.27 | 162.23 | 109.92 | 140.00 | |
Average Payables |
42.79 | 36.62 | 44.73 | 35.00 | |
Average Inventory |
55.60 | 52.75 | 50.52 | 48.50 | |
Average Assets |
1,188.72 | 1,285.13 | 1,303.96 | 1,517.50 | |
Average Common Equity |
(183.42) | (69.86) | (45.88) | 87.50 |
Columns are period end dates · fundamentals updated 6 Nov 2026